Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAIC 2021 | Highlights from AAIC: Targeting the immune response to treat AD

Jacobo E. Mintzer, MD, of the Medical University of South Carolina, discusses the emphasis on inflammation and the immune response in the treatment of Alzheimer’s disease (AD), seen at the 2021 Alzheimer’s Association International Conference (AAIC). He notes that several studies were presented looking at new potential targets for the treatment of AD, based on better management of the immune response. This interview took place during the Alzheimer’s Association International Conference (AAIC), 2021.


Prof. Mintzer reports the following disclosures:
AARP – Global Council on Brain Health, AARP – Staying Sharp, ACADIA, ACTC/ATRI, Alzheimer’s Association (local and national), BioPharma Connex, Cerevel Therapeutics, Genentech Pharmaceuticals, International Psychogeriatric Association, NeuroQuest, Praxis Pharmaceuticals, Recruitment Partners LLC, Technology Accelerator Company, Elder Court.